In some embodiments, the pharmaceutical formulation may include one or more polymers at a concentration of from about 0.0001% (w/w) to about 0.001% (w/w), from about 0.001% (w/w) to about 0.01% (w/w), from about 0.01 % (w/w) to about 0.1 % (w/w), from about 0.1% (w/w) to about 1% (w/w), from about 0.1 % (w/w) to about 10% (w/w), from about 0.5% (w/w) to about 5% (w/w), from about 1% (w/w) to about 10% (w/w),from about 2% (w/w) to about 30% (w/w), from about 5% (w/w) to about 15% (w/w), from about 10% (w/w) to about 30% (w/w), from about 10% (w/w) to about 40% (w/w), from about 15% (w/w) to about 45% (w/w), from about 20% (w/w) to about 55% (w/w), from about 25% (w/w) to about 65% (w/w), from about 30% (w/w) to about 70% (w/w), from about 35% (w/w) to about 75% (w/w), from about 40% (w/w) to about 80% (w/w), from about 50% (w/w) to about 85% (w/w), from about 60% (w/w) to about 90% (w/w), from about 75% (w/w) to about 95% (w/w), from about 90% (w/w) to about 96% (w/w), from about 92% (w/w) to about 98% (w/w), from about 95% (w/w) to about 99% (w/w), from about 98% (w/w) to about 99.5% (w/w), and/or from about 99% (w/w) to about 99.9% (w/w)
F.KhanA
In addition, by suppressing the expression of -SMA and FN and inducing the blockage of EMT, AS-IV can prevent UII-treated NRK-52E cells from losing epithelial cell morphology and acquiring the mesenchymal phenotype
FabeloNMartnVSantpereGMarnRTorrentLFerrerIet al
